TheraRadar
← Back
Data updated: May 24, 2026

G AND W LABS INC

Generics

G AND W LABS INC is a generic drug manufacturer focused on Dermatology, Neurology, Immunology.

1982
Since
12
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
May 31, 2026 — CTx-1301 (dexmethylphenidate)
5d
Jun 1, 2026 — tebipenem HBr
Jun 29, 2026 — LNTH-2501 (Gallium 68 edotreotide)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Dermatology 25%
1 drugs
Neurology 25%
1 drugs
Immunology 25%
1 drugs
Gastroenterology 25%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling